8-K filing — ACADIA PHARMACEUTICALS INC (ACAD)
Filed: 2026-09-11 AccNo: 0001193125-26-389400 Size: 604 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action
On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.